Search Result

Results for "

β-thalassemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcl-2 Family (4) Biochemical Assay Reagents (1) Ferrochelatase (1) Ferroportin (2) Ferroptosis (3) GLP Receptor (1) Histone Acetyltransferase (1) Histone Methyltransferase (4) Isotope-Labeled Compounds (1) Pyruvate Kinase (1) Reference Standards (1) Ser/Thr Protease (3) TGF-beta/Smad (1)
By Research Areas:	Cardiovascular Disease (10) Metabolic Disease (5)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131060

CN128 hydrochloride CN328	Ferroptosis	Others
CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-139400

Pociredir FTX-6058	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-139400A

Pociredir hydrochloride FTX-6058 hydrochloride	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-16912

Petadeferitrin SP-420	Ferroptosis	Metabolic Disease
Petadeferitrin (SP-420) is a tridentate iron chelator belonging to the class of iron chelators, with orally activity. Petadeferitrin can be used in research related to β-thalassemia .

HY-112220

VIT-2763	Ferroportin	Metabolic Disease
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .

HY-P991637

REGN7999	Ser/Thr Protease	Metabolic Disease
REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .

HY-160078

Deferiprone O-β-D-glucuronide	Others	Metabolic Disease
Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-W015881A

Dimebutic acid sodium NSC-16045 sodium; NSC-741804 sodium	Bcl-2 Family	Cardiovascular Disease
Dimebutic acid sodium is an orally active short-chain fatty acid. Dimebutic acid sodium stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid sodium prolongs red blood cell survival. Dimebutic acid sodium exhibits toxicity in rats. Dimebutic acid sodium can be used in the study of β-thalassemia and sickle cell disease .

HY-W015881

Dimebutic acid NSC-16045; NSC-741804	Bcl-2 Family	Cardiovascular Disease
Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease .

HY-W015881R

Dimebutic acid (Standard) NSC-16045 (Standard); NSC-741804 (Standard)	Reference Standards Bcl-2 Family	Cardiovascular Disease
Dimebutic acid (Standard) is an analytical standard of Dimebutic acid (HY-W015881). This product is intended for research and analytical applications. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease .

HY-114758

Pyridoxal isonicotinoyl hydrazone 4 Publications Verification	Biochemical Assay Reagents Ferrochelatase	Cardiovascular Disease
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .

HY-W699526

Dimebutic acid-d6 NSC-16045-d₆; NSC-741804-d₆	Isotope-Labeled Compounds Bcl-2 Family	Cardiovascular Disease
Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

HY-108260

Deferitrin GT-56-252	Ferroptosis	Cardiovascular Disease
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .

HY-130136A

TMPRSS6-IN-1 TFA	Ser/Thr Protease	Others
TMPRSS6-IN-1 (TFA) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .

HY-130136

TMPRSS6-IN-1	Ser/Thr Protease	Others
TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .

HY-169761

(rac)-dWIZ-1	Histone Methyltransferase	Cardiovascular Disease
WIZ-IN-1 (Example 2) is a Wiz inhibitor (DC₅₀: 0.36 μM). WIZ-IN-1 can be used for research of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta- hemoglobinopathies), such as sickle cell disease and beta-thalassemia .

HY-163819

WIZ degrader 3	Histone Acetyltransferase	Cardiovascular Disease
WIZ degrader 3 (Compound 29) is a degrader for widely interspaced zinc finger motifs (WIZ), with an AC₅₀ of 6.4 nM. WIZ degrader 3 induces the expression of fetal hemoglobin (HbF), with an EC₅₀ of 45 nM. WIZ degrader 3 can be used for the research of blood disorders, such as sickle cell disease and β- thalassemia .

HY-159095

PKR activator 5	Pyruvate Kinase	Others
PKR activator 5 (Compound 18) is an activator for pyruvate kinase R (PKR) with an AC₅₀ of 28 nM .

HY-170831

DS79932728	Histone Methyltransferase GLP Receptor	Others
DS79932728 is an orally active inhibitor for G9a and GLP with IC₅₀ of 12.6 nM and 75.7 nM. DS79932728 induces the production of γ-globin, thereby increasing the level of fetal hemoglobin (HbF). DS79932728 increases F-reticulocytes (F-rets) proportion and exhibits good oral absorption characteristics in cynomolgus monkey models .

Cat. No.	Product Name	Target	Research Area

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

Cat. No.	Product Name	Target	Research Area

HY-P991637

REGN7999	Ser/Thr Protease	Metabolic Disease
REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

Cat. No.	Product Name	Chemical Structure

HY-W699526

Dimebutic acid-d6
Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

Dimebutic acid-d6

Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

Cat. No.	Product Name		Classification

HY-159095

PKR activator 5		Azide
PKR activator 5 (Compound 18) is an activator for pyruvate kinase R (PKR) with an AC₅₀ of 28 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.